A continuous infusion of etoposide and doxorubicin for refractory MAS management
1Department of Haematology, PLA 251 Hospital, Zhang Jia Kou, Hebei, China.
The Netherlands Journal of Medicine
|August 31, 2016
Abstract
No abstract available in PubMed .
Related Concept Videos
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
326
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
326


